Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Evaluation of the Effects of Anti-TNF Therapy on the Retina in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis

10. november 2026 oppdatert av: Muhammet Ali Gürsoy, Ankara City Hospital Bilkent

EVALUATION OF THE EFFECTS OF ANTI-TNF THERAPY ON THE RETINA IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS

This prospective observational cohort study evaluates whether anti-tumor necrosis factor (anti-TNF) therapy changes the retinal and choroidal microvasculature and retinal structure in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS). Patients for whom the rheumatology clinic decided to start anti-TNF therapy as part of routine care are compared with patients who continue treatment without anti-TNF agents. All participants undergo a complete eye examination, optical coherence tomography (OCT) and OCT angiography (OCTA) before treatment and at month 6. The main question is whether retinal vessel density changes differently over time between the two groups.

Studieoversikt

Detaljert beskrivelse

Background: Chronic systemic inflammation in RA and AS has been associated with endothelial dysfunction and microvascular changes. TNF-alpha is a key mediator of this inflammation, and anti-TNF agents are widely used in both diseases. Prospective data on retinal and choroidal microvasculature with measurements taken before the start of anti-TNF therapy are limited.

Design and participants: Patients with RA or AS followed at the Rheumatology Clinic of Ankara Bilkent City Hospital were referred to the Ophthalmology Clinic between October and December 2025. Treatment decisions were made by the treating rheumatologists, independently of the study. The anti-TNF group consists of anti-TNF-naive patients for whom anti-TNF therapy was planned; their baseline examination was performed before the first dose. The control group consists of patients who were not receiving anti-TNF therapy at baseline and did not start it during the 6-month follow-up.

Assessments: At baseline and month 6, all participants undergo best-corrected visual acuity (logMAR), Goldmann applanation tonometry, slit-lamp biomicroscopy and dilated fundus examination with a +90 D lens. OCT (Heidelberg Spectralis) is used to measure central and sectoral macular thickness, peripapillary retinal nerve fiber layer (RNFL) thickness (global and six sectors) and ganglion cell layer (GCL) thickness. OCTA (RTVue XR Avanti with AngioVue, Optovue) is performed with fovea-centred 6x6 mm scans. Superficial (SCP) and deep capillary plexus (DCP) vessel density are recorded for the whole image, superior and inferior hemifields, and foveal, parafoveal and perifoveal regions with four sectors. Foveal avascular zone (FAZ) area, FAZ perimeter, acircularity index, foveal vessel density and choriocapillaris flow area are also recorded. 3D projection artifact removal is applied. Scans with a quality (Q) score below 6, significant motion or projection artifacts, or segmentation errors are excluded. All examinations are performed by the same, unmasked examiner. ESR and CRP values closest to each visit are obtained from hospital records.

Statistical analysis: Eye-level data are analysed with linear mixed models adjusted for age and sex. The treatment effect is assessed by the group-by-time interaction. The study is reported according to the STROBE guideline.

Studietype

Observasjonsmessig

Registrering (Faktiske)

53

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Adult patients with rheumatoid arthritis or ankylosing spondylitis followed at the Rheumatology Clinic of Ankara Bilkent City Hospital and referred to the Ophthalmology Clinic between October and December 2025.

Beskrivelse

Inclusion Criteria:

  • Age 18 to 75 years
  • Diagnosis of rheumatoid arthritis or ankylosing spondylitis
  • Receiving treatment for RA or AS (conventional therapy, planned initiation of anti-TNF therapy, or continued conventional non-biologic therapy)
  • Willingness to participate and written informed consent

Exclusion Criteria:

  • • History of retinal disease (e.g., diabetic retinopathy, age-related macular degeneration, retinal vein occlusion)

    • Ocular disease that may affect OCT measurements or visual field, such as glaucoma, optic neuropathy or dense cataract
    • Uveitis, diabetes mellitus or systemic hypertension
    • Previous ocular surgery or laser treatment, or high refractive error
    • Pregnancy or breastfeeding
    • Treatment with non-TNF biologic agents (e.g., abatacept, rituximab)
    • OCTA scan quality (Q) score below 6

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Anti-TNF group

Anti-TNF-naive patients with RA or AS for whom the treating rheumatologist planned to start anti-TNF therapy as part of routine care. The baseline examination was performed before the first dose.

adalimumab, etanercept, golimumab

Andre navn:
  • TNF inhibitor prescribed by the treating rheumatologist according to routine clinical practice; not assigned by the study protocol.
Control group

Patients with RA or AS who were not receiving anti-TNF therapy at baseline and did not start it during the 6-month follow-up. They continued conventional (non-biologic) treatment.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in superficial capillary plexus whole-image vessel density
Tidsramme: Baseline and month 6

SCP vessel density (%) in fovea-centred 6x6 mm OCTA scans (AngioVue, Optovue). Change from baseline to month 6 is compared between groups (group-by-time interaction).

Baseline and month 6
Change in deep capillary plexus whole-image vessel density
Tidsramme: Baseline and month 6

DCP vessel density (%) in fovea-centred 6x6 mm OCTA scans. Change from baseline to month 6 is compared between groups.

Baseline and month 6

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Erythrocyte sedimentation (mm/h) rate
Tidsramme: Baseline and month 6

Change in systemic inflammatory marker obtained from hospital records.

Baseline and month 6
C-reactive protein (mg/L) value
Tidsramme: Baseline and month 6

Change in systemic inflammatory marker obtained from hospital records.

Baseline and month 6

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Yasin Toklu, Professor Doctor, Ankara City Hospital Bilkent

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. november 2025

Primær fullføring (Faktiske)

23. juni 2026

Studiet fullført (Faktiske)

23. juni 2026

Datoer for studieregistrering

Først innsendt

18. oktober 2026

Først innsendt som oppfylte QC-kriteriene

10. november 2026

Først lagt ut (Faktiske)

12. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be shared publicly. Aggregate results will be reported in scientific publications.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere